https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-14 17:16:082025-05-19 17:47:56Long-term Administration of Diazoxide Choline Extended-Release (DCCR) Tablets in People with Prader-Willi Syndrome: Changes in Lean Body Mass and Lean Mass Index
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-14 17:13:412025-05-17 16:40:00Pediatric Endocrine Society, 2025
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-14 17:03:512025-05-17 16:40:25Academy of Managed Care Pharmacy, 2025
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-11 10:39:142025-05-17 16:40:56Design of a Randomized Withdrawal Period Following Long-Term Administration of Diazoxide Choline Extended-Release Tablets to People with Prader-Willi Syndrome
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-11 10:33:422025-05-17 16:41:12Withdrawal of Diazoxide Choline Extended-Release (DCCR) Tablets Worsens Hyperphagia and Increases Weight and BMI in a 16-Week Double-Blind, Placebo-Controlled, Randomized Withdrawal Period in Patients With Prader-Willi Syndrome
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-11 10:29:262025-05-17 16:41:28Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Participants with Prader-Willi Syndrome from the Completed C601 Randomized Double-Blind Placebo-Controlled Study (DESTINY PWS) and C602 Open Label Extension (OLE) Study
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-11 10:26:412025-05-17 16:41:47Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in Clinical Trials of Diazoxide Choline Extended Release (DCCR) in Participants with Prader-Willi Syndrome.
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2025-03-11 10:23:092025-05-17 16:42:04Long-term Efficacy Results of Diazoxide Choline Extended-Release (DCCR) Tablets in Participants with Prader-Willi Syndrome from the Completed C601 (DESTINY PWS) and C602 Open Label Extension (OLE) Studies.
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2024-11-16 09:00:352025-05-14 18:51:19European Society for Paediatric Endocrinology, 2024
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
0
0
sol3ma
https://www.solenomedicalaffairs.com/wp-content/uploads/2025/01/Soleno_MA_Logo.png
sol3ma2024-06-01 09:00:052025-03-26 12:00:31Endocrine Society Annual Meeting, 2024
